vs
Side-by-side financial comparison of Protagonist Therapeutics, Inc (PTGX) and TOMPKINS FINANCIAL CORP (TMP). Click either name above to swap in a different company.
TOMPKINS FINANCIAL CORP is the larger business by last-quarter revenue ($194.8M vs $170.6M, roughly 1.1× Protagonist Therapeutics, Inc). Protagonist Therapeutics, Inc runs the higher net margin — 77.2% vs 49.4%, a 27.8% gap on every dollar of revenue. On growth, Protagonist Therapeutics, Inc posted the faster year-over-year revenue change (184.4% vs 152.7%). Protagonist Therapeutics, Inc produced more free cash flow last quarter ($182.8M vs $31.9M).
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel peptide-based targeted therapies for unmet medical needs, primarily covering gastrointestinal disorders, inflammatory diseases and rare disease indications. Its lead product candidates target inflammatory bowel disease and other chronic immune-related conditions, with operations spanning global R&D and partnership collaborations.
Tompkins Financial Corporation is a small, diversified financial services company based in Ithaca, New York. It is the parent of the Tompkins Trust Company, as well as several other banks, an insurance agency, and a wealth management division.
PTGX vs TMP — Head-to-Head
Income Statement — Q4 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $170.6M | $194.8M |
| Net Profit | $131.7M | $96.2M |
| Gross Margin | — | — |
| Operating Margin | 74.3% | 71.7% |
| Net Margin | 77.2% | 49.4% |
| Revenue YoY | 184.4% | 152.7% |
| Net Profit YoY | 381.7% | 388.9% |
| EPS (diluted) | $2.01 | $6.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $194.8M | ||
| Q3 25 | — | $87.4M | ||
| Q2 25 | — | $82.6M | ||
| Q1 25 | — | $81.7M | ||
| Q4 24 | $170.6M | $77.1M | ||
| Q3 24 | — | $76.6M | ||
| Q2 24 | — | $72.7M | ||
| Q1 24 | $255.0M | $72.8M |
| Q4 25 | — | $96.2M | ||
| Q3 25 | — | $23.7M | ||
| Q2 25 | — | $21.5M | ||
| Q1 25 | — | $19.7M | ||
| Q4 24 | $131.7M | $19.7M | ||
| Q3 24 | — | $18.6M | ||
| Q2 24 | — | $15.7M | ||
| Q1 24 | $207.3M | $16.9M |
| Q4 25 | — | 71.7% | ||
| Q3 25 | — | 35.6% | ||
| Q2 25 | — | 34.2% | ||
| Q1 25 | — | 31.6% | ||
| Q4 24 | 74.3% | 33.4% | ||
| Q3 24 | — | 32.0% | ||
| Q2 24 | — | 28.3% | ||
| Q1 24 | 80.9% | 30.4% |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 27.1% | ||
| Q2 25 | — | 26.0% | ||
| Q1 25 | — | 24.1% | ||
| Q4 24 | 77.2% | 25.5% | ||
| Q3 24 | — | 24.3% | ||
| Q2 24 | — | 21.6% | ||
| Q1 24 | 81.3% | 23.2% |
| Q4 25 | — | $6.72 | ||
| Q3 25 | — | $1.65 | ||
| Q2 25 | — | $1.50 | ||
| Q1 25 | — | $1.37 | ||
| Q4 24 | $2.01 | $1.39 | ||
| Q3 24 | — | $1.30 | ||
| Q2 24 | — | $1.10 | ||
| Q1 24 | $3.26 | $1.18 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $418.9M | $132.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $675.3M | $938.4M |
| Total Assets | $744.7M | $8.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $132.8M | ||
| Q3 25 | — | $193.5M | ||
| Q2 25 | — | $212.6M | ||
| Q1 25 | — | $193.1M | ||
| Q4 24 | $418.9M | $134.4M | ||
| Q3 24 | — | $132.3M | ||
| Q2 24 | — | $70.9M | ||
| Q1 24 | $322.6M | $57.1M |
| Q4 25 | — | $938.4M | ||
| Q3 25 | — | $788.8M | ||
| Q2 25 | — | $761.8M | ||
| Q1 25 | — | $741.4M | ||
| Q4 24 | $675.3M | $713.4M | ||
| Q3 24 | — | $719.9M | ||
| Q2 24 | — | $674.6M | ||
| Q1 24 | $560.4M | $667.9M |
| Q4 25 | — | $8.7B | ||
| Q3 25 | — | $8.5B | ||
| Q2 25 | — | $8.4B | ||
| Q1 25 | — | $8.2B | ||
| Q4 24 | $744.7M | $8.1B | ||
| Q3 24 | — | $8.0B | ||
| Q2 24 | — | $7.9B | ||
| Q1 24 | $629.3M | $7.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $184.2M | $38.9M |
| Free Cash FlowOCF − Capex | $182.8M | $31.9M |
| FCF MarginFCF / Revenue | 107.1% | 16.4% |
| Capex IntensityCapex / Revenue | 0.8% | 3.6% |
| Cash ConversionOCF / Net Profit | 1.40× | 0.40× |
| TTM Free Cash FlowTrailing 4 quarters | $101.7M | $105.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $38.9M | ||
| Q3 25 | — | $34.9M | ||
| Q2 25 | — | $18.9M | ||
| Q1 25 | — | $22.2M | ||
| Q4 24 | $184.2M | $95.0M | ||
| Q3 24 | — | $21.2M | ||
| Q2 24 | — | $27.3M | ||
| Q1 24 | $-27.4M | $23.2M |
| Q4 25 | — | $31.9M | ||
| Q3 25 | — | $33.9M | ||
| Q2 25 | — | $18.3M | ||
| Q1 25 | — | $20.9M | ||
| Q4 24 | $182.8M | $88.8M | ||
| Q3 24 | — | $18.9M | ||
| Q2 24 | — | $26.3M | ||
| Q1 24 | $-27.7M | $21.9M |
| Q4 25 | — | 16.4% | ||
| Q3 25 | — | 38.8% | ||
| Q2 25 | — | 22.1% | ||
| Q1 25 | — | 25.5% | ||
| Q4 24 | 107.1% | 115.1% | ||
| Q3 24 | — | 24.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | -10.9% | 30.0% |
| Q4 25 | — | 3.6% | ||
| Q3 25 | — | 1.1% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 1.7% | ||
| Q4 24 | 0.8% | 8.1% | ||
| Q3 24 | — | 2.9% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | 0.1% | 1.9% |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 1.47× | ||
| Q2 25 | — | 0.88× | ||
| Q1 25 | — | 1.13× | ||
| Q4 24 | 1.40× | 4.82× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.74× | ||
| Q1 24 | -0.13× | 1.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
